Identification | Back Directory | [Name]
4-Piperidinone, 1-methyl-3,5-bis[(3,4,5-trimethoxyphenyl)methylene]-, (3E,5E)- | [CAS]
1195795-93-7 | [Synonyms]
4-Piperidinone, 1-methyl-3,5-bis[(3,4,5-trimethoxyphenyl)methylene]-, (3E,5E)- | [Molecular Formula]
C26H31NO7 | [MOL File]
1195795-93-7.mol | [Molecular Weight]
469.53 |
Chemical Properties | Back Directory | [Melting point ]
151-152 °C(Solv: ethanol (64-17-5)) | [Boiling point ]
644.0±55.0 °C(Predicted) | [density ]
1.192±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
5.03±0.20(Predicted) | [color ]
Light yellow to yellow |
Hazard Information | Back Directory | [Description]
RL71 is a sselective inhibitor of SERCA2, specially binding to SERCA2 at a novel site, suppressing the Ca2+-ATPase activity of SERCA2, inducing apoptosis and downregulating Akt. | [Uses]
RL71 is a curcuminoid anticancer agent that exhibits potent cytotoxicity against a variety of ER-negative breast cancer cells. RL71 (1 μM) induces cell cycle arrest in the G2/M phase and induces apoptosis in SKBr3 cells. RL7 also decreases HER2/neu phosphorylation and increases p27. RL71 also significantly reduced the phosphorylation of Akt and transiently increased the stress kinases JNK1/2 and p38 MAPK. Furthermore, RL71 exhibited anti-angiogenic potential in vitro, inhibiting the migration of HUVEC cells and the ability of these cells to form tubular networks[1]. | [References]
[1] RL71, a second-generation curcumin analog, induces apoptosis and downregulates Akt in ER-negative breast cancer cells |
|
|